Crossover design | |||||
---|---|---|---|---|---|
Screening | Baseline | Follow up | |||
Visit 1 | Visit 2, 5 | Visit 3, 6 | Visit 4, 7 | (Visit 8) | |
D-28 | Week 0 | Week 6 | Week 12 | Week 24 | |
~D-1 | D0 | D42 | D84 | D168 | |
Informed consent form | ◯ | ||||
Demographic information taking 1 | ◯ | ||||
Medical history taking | ◯ | ||||
Inclusion/exclusion criteria check | ◯ | ◯ | |||
Physician examination 2 | ◯ | ◯ | ◯ | ||
Drinking/smoking taking status 3 | ◯ | ◯ | |||
Vital sign measurement | ◯ | ◯ | ◯ | ◯ | ◯ |
Concomitant drugs check | ◯ | ◯ | ◯ | ◯ | ◯ |
Anthropometric measures 4 | ◯ | ◯ | ◯ | ◯ | |
Glucose parameter 5 | ◯ | ◯ | |||
Lipid profile 6 | ◯ | ◯ | |||
Adipocytokine 7 | ◯ | ◯ | |||
Carnitine assay | ◯ | ◯ | |||
Laboratory test 8 | ◯ | ◯ | |||
Study product distribution | ◯ | ◯ | |||
Compliance checking | ◯ | ◯ | |||
Adverse event monitoring | ◯ | ◯ | ◯ | ◯ | |
Diet, physical exercisecounseling 9 | ◯ | ◯ | ◯ | ◯ |